RecruitingPhase 1NCT07304128
A Study of PLB-002 in Advanced Solid Tumors
Studying Multiple endocrine neoplasia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Primelink BioTherapeitics(ShenZhen) Limited
- Intervention
- PLB-002(drug)
- Enrollment
- 100 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2026 – 2027
Study locations (2)
- Fudan University Shanghai Cancer Center- Gynecology Onc, Shanghai, Shanghai Municipality, China
- Fudan University Shanghai Cancer Center- Phase 1, Shanghai, Shanghai Municipality, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07304128 on ClinicalTrials.govOther trials for Multiple endocrine neoplasia
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07521436Awareness of Risk Factors and Perception of Cardiovascular Risk in Secondary Prevention Among Women and MenIstituti Clinici Scientifici Maugeri SpA
- RECRUITINGEARLY PHASE1NCT06888102A Platform Study of Epigenetic Therapy Before Prostatectomy in Men With Prostate CancerEdwin Posadas, MD
- RECRUITINGNANCT07499167BRAHMS: Bed Rest And HypoMetabolism StudyCentre National d'Etudes Spatiales
- ACTIVE NOT RECRUITINGNCT07518212OST and MORES in Male OsteoporosisKayseri City Hospital
- RECRUITINGNANCT07187518Clinical Study to Estimate Bone Mineral Density With the POROUS Ultrasound DevicePOROUS GmbH
- RECRUITINGPHASE4NCT07397403The Efficacy of Doxycycline Post Exposure Prophylaxis for Preventing STIs Among MSM in Bangkok, Thailand.Bangrak STIs Center
- RECRUITINGNANCT07217834Effects of a Glycerol-Electrolyte Beverage on Fluid Balance in Healthy Euhydrated Men and WomenPepsiCo Global R&D
- RECRUITINGPHASE3NCT06952803A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA MutationAstraZeneca